Download PDF
Semin Thromb Hemost 2020; 46(01): 032-037
DOI: 10.1055/s-0039-1695736
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Using Plasma and Prothrombin Complex Concentrates

Jerrold H. Levy
1   Division of Cardiothoracic Anesthesiology and Critical Care, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina
,
Kamrouz Ghadimi
1   Division of Cardiothoracic Anesthesiology and Critical Care, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina
,
Nathan H. Waldron
1   Division of Cardiothoracic Anesthesiology and Critical Care, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina
,
Jean M. Connors
2   Department of Hematology, Harvard Medical School, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
19 September 2019 (online)

    Permissions and Reprints

Abstract

Surgical patients, following procedural interventions or traumatic injury, often bleed due to ongoing blood loss or coagulopathy. Volume resuscitation and transfusion management are critical for the massively bleeding patient. While transfusions may correct coagulopathy, they carry multiple risks including circulatory overload and transfusion-related acute lung injury. Factor concentrates, specifically prothrombin complex concentrates (PCCs), are often used as part of multimodal therapy for bleeding along with laboratory testing to rapidly assess underlying coagulopathy. Although they are commonly used as part of management algorithms, studies evaluating their efficacy against fresh frozen plasma (FFP) or other potential therapies are needed. Further, PCCs are indicated to treat the coagulopathy associated with non-vitamin K oral anticoagulants in the perioperative setting. The focus of this commentary will be the perioperative use of PCCs, plasma, and FFP.

Keywords

factor concentrates - fibrinogen - fresh frozen plasma - hemorrhage - plasma - prothrombin complex concentrates
 

  • References

  • 1 Ghadimi K, Levy JH, Welsby IJ. Perioperative management of the bleeding patient. Br J Anaesth 2016; 117 (Suppl. 03) iii18-iii30
    CrossrefPubMedGoogle Scholar
  • 2 Sniecinski RM, Chandler WL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg 2011; 113 (06) 1319-1333
    CrossrefPubMedGoogle Scholar
  • 3 Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 2018; 15 (05) 273-281
    CrossrefPubMedGoogle Scholar
  • 4 Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014; 54 (05) 1389-1405 , quiz 1388
    CrossrefPubMedGoogle Scholar
  • 5 Grottke O, Levy JH. Prothrombin complex concentrates in trauma and perioperative bleeding. Anesthesiology 2015; 122 (04) 923-931
    CrossrefPubMedGoogle Scholar
  • 6 Ghadimi K, Levy JH, Welsby IJ. Prothrombin complex concentrates for bleeding in the perioperative setting. Anesth Analg 2016; 122 (05) 1287-1300
    CrossrefPubMedGoogle Scholar
  • 7 Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. ; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Work Group. Recommendations for the transfusion of plasma and platelets. Blood Transfus/ Trasfusione Del Sangue 2009; 7 (02) 132-150
    PubMedGoogle Scholar
  • 8 Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012; 52 (Suppl. 01) 65S-79S
    CrossrefPubMedGoogle Scholar
  • 9 Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. ; British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135 (05) 634-641
    CrossrefPubMedGoogle Scholar
  • 10 O'Shaughnessy DF, Atterbury C, Bolton Maggs P. , et al; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126 (01) 11-28
    CrossrefPubMedGoogle Scholar
  • 11 Tran HA, Chunilal SD, Harper PL, Tran H, Wood EM, Gallus AS. ; Australasian Society of Thrombosis and Haemostasis (ASTH). An update of consensus guidelines for warfarin reversal. Med J Aust 2013; 198 (04) 198-199
    CrossrefPubMedGoogle Scholar
  • 12 Scully M, Hunt BJ, Benjamin S. , et al; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158 (03) 323-335
    CrossrefPubMedGoogle Scholar
  • 13 Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion 2012; 52 (Suppl. 01) 9S-19S
    CrossrefPubMedGoogle Scholar
  • 14 Huisman EL, de Silva SU, de Peuter MA. Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States. Transfus Apheresis Sci 2014; 51 (01) 17-24
    CrossrefPubMedGoogle Scholar
  • 15 Spinella PC, Frazier E, Pidcoke HF. , et al. All plasma products are not created equal: Characterizing differences between plasma products. J Trauma Acute Care Surg 2015; 78 (06) (Suppl. 01) S18-S25
    CrossrefPubMedGoogle Scholar
  • 16 Desborough M, Stanworth S. Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures. Transfusion 2012; 52 (Suppl. 01) 20S-29S
    CrossrefPubMedGoogle Scholar
  • 17 Kozek-Langenecker S, Sørensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011; 15 (05) R239
    CrossrefPubMedGoogle Scholar
  • 18 Watson GA, Sperry JL, Rosengart MR. , et al; Inflammation and Host Response to Injury Investigators. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma 2009; 67 (02) 221-227 , discussion 228–230
    CrossrefPubMedGoogle Scholar
  • 19 Inaba K, Branco BC, Rhee P. , et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg 2010; 210 (06) 957-965
    CrossrefPubMedGoogle Scholar
  • 20 Sarani B, Dunkman WJ, Dean L, Sonnad S, Rohrbach JI, Gracias VH. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med 2008; 36 (04) 1114-1118
    CrossrefPubMedGoogle Scholar
  • 21 Khan H, Belsher J, Yilmaz M. , et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007; 131 (05) 1308-1314
    CrossrefPubMedGoogle Scholar
  • 22 Innerhofer P, Westermann I, Tauber H. , et al. The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury 2013; 44 (02) 209-216
    CrossrefPubMedGoogle Scholar
  • 23 Kaufman R, Anderson K. Transfusion-associated graft-versus-host disease. In: Kufe DW, Pollock RE, Weichselbaum RR. , et al., eds. Holland-Frei Cancer Medicine, 6th ed. Hamilton, Ontario: BC Decker; 2003
    Google Scholar
  • 24 Lin Y, Saw CL, Hannach B, Goldman M. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion 2012; 52 (03) 567-574
    CrossrefPubMedGoogle Scholar
  • 25 Chapman CE, Stainsby D, Jones H. , et al; Serious Hazards of Transfusion Steering Group. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009; 49 (03) 440-452
    CrossrefPubMedGoogle Scholar
  • 26 Lucas G, Win N, Calvert A. , et al. Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. Vox Sang 2012; 103 (01) 10-17
    CrossrefPubMedGoogle Scholar
  • 27 Food and Drug Administration. Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2012. Silver Springs, MD: US Food and Drug Administration; 2014
    Google Scholar
  • 28 Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother 2011; 38 (01) 65-70
    CrossrefPubMedGoogle Scholar
  • 29 Kozek-Langenecker SA, Afshari A, Albaladejo P. , et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30 (06) 270-382
    CrossrefPubMedGoogle Scholar
  • 30 Levy JH, Grottke O, Fries D, Kozek-Langenecker S. Therapeutic plasma transfusion in bleeding patients: a systematic review. Anesth Analg 2017; 124 (04) 1268-1276
    CrossrefPubMedGoogle Scholar
  • 31 Levy JH, Douketis J, Steiner T, Goldstein JN, Milling TJ. Prothrombin complex concentrates for perioperative vitamin K antagonist and non-vitamin K anticoagulant reversal. Anesthesiology 2018; 129 (06) 1171-1184
    CrossrefPubMedGoogle Scholar
  • 32 Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109 (05) 918-926
    CrossrefPubMedGoogle Scholar
  • 33 Brown KS, Zahir H, Grosso MA, Lanz HJ, Mercuri MF, Levy JH. Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. Crit Care 2016; 20 (01) 273
    CrossrefPubMedGoogle Scholar
  • 34 Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care 2010; 12 (03) 403-413
    CrossrefPubMedGoogle Scholar
  • 35 Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United kingdom. Clin Ther 2010; 32 (14) 2478-2493
    CrossrefPubMedGoogle Scholar
  • 36 Görlinger K, Dirkmann D, Hanke AA. , et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011; 115 (06) 1179-1191
    CrossrefPubMedGoogle Scholar
  • 37 Weber CF, Zacharowski K, Meybohm P. , et al. Hemotherapy algorithms for coagulopathic cardiac surgery patients. Clin Lab 2014; 60 (06) 1059-1063
    PubMedGoogle Scholar
  • 38 Schöchl H, Voelckel W, Grassetto A, Schlimp CJ. Practical application of point-of-care coagulation testing to guide treatment decisions in trauma. J Trauma Acute Care Surg 2013; 74 (06) 1587-1598
    CrossrefPubMedGoogle Scholar
  • 39 Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood 2015; 125 (09) 1387-1393
    CrossrefPubMedGoogle Scholar
  • 40 Görlinger K, Fries D, Dirkmann D, Weber CF, Hanke AA, Schöchl H. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus Med Hemother 2012; 39 (02) 104-113
    CrossrefPubMedGoogle Scholar
  • 41 Pollack Jr CV, Reilly PA, Eikelboom J. , et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
    CrossrefPubMedGoogle Scholar
  • 42 Zahir H, Brown KS, Vandell AG. , et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131 (01) 82-90
    CrossrefPubMedGoogle Scholar